PE21.04LB Advances in the use of a bacterially derived glycoside for inducing oligomannose-targeted neutralizing antibodies to HIV-1E-posterNovel vaccine and other prevention approaches
PE21.05LB Immunization with HIV-1 fusion peptide carrier conjugate in a cocktail with HIV-envelope trimer elicits potent and cross-clade neutralization activity in guinea pigsE-posterNovel vaccine and other prevention approaches
PE21.07LB HIV-1 fusion peptide (FP) conjugate and envelope trimer cocktail immunization elicit diverse FP-directed neutralizing antibodies in non-human primatesE-posterNovel vaccine and other prevention approaches
PE22.01 Directly Observed Therapy (DOT) can be Implemented Successfully in Research Settings to Evaluate PrEP PK among Pregnant and Postpartum Adolescents and Young Women in AfricaE-posterNovel vaccine and other prevention approaches
PE22.02 MRI examination of cabotegravir long-acting formulation depot kinetics in healthy adult volunteersE-posterPharmacology/PK and PD studies
PE22.03 Impact of UGT induction by rifampin and rifabutin on cabotegravir long-acting pharmacokinetics for HIV pre-exposure prophylaxis (PrEP) using population pharmacokinetic modeling and simulationE-posterPharmacology/PK and PD studies
PE23.01 Identifying regional disparities in access to HIV and sexual health resources for young men who have sex with men in the United States: The iREACH StudyE-posterPolicy and advocacy
PE23.02 Adoption of WHO's HIV retesting policy for HIV-negative women during the breastfeeding period in 10 high HIV-burden African countriesE-posterPolicy and advocacy
PE23.03 Ten years of the AVAC Advocacy Fellows Program: An evaluationE-posterPolicy and advocacy
PE23.04 Pathogen reduction (PR) as an alternative to donor deferral to mitigate the risk of transfusion-transmitted HIVE-posterPolicy and advocacy
seek-warrow-warrow-eseek-e401 - 410 of 444 items